Rongchang Bio: The Phase III clinical trial of Tacrolimus in the treatment of primary Sjgren's syndrome has reached the main research endpoint.

Rongchang Biotech announced that the company's independently developed BLyS/APRIL dual-target fusion protein innovative drug Tezepimab for the treatment of primary Sjgren's syndrome has completed Phase III clinical trials, reaching the clinical trial's main study endpoints as per the protocol design. Tezepimab can effectively and sustainably improve the clinical symptoms of Sjgren's syndrome patients, demonstrating good efficacy and safety. The company will submit a marketing application to the National Medical Products Administration Drug Evaluation Center as soon as possible, and detailed data will be disclosed at international major academic conferences.